A special treat this week as the two titans of psychopharmacology discuss the medicinal chemistry of psychedelics. Dr Nichols is the Founding President of the Heffter Research Institute, an organisation designed to promote research of the highest scientific quality with psychedelics in order to contribute to a greater understanding of the mind leading to the improvement of the human condition, and to alleviate suffering.
Professor Nutt and Dr Nichols answer some burning questions of psychedelic science such as:
What will come to market first, LSD, Psilocybin or MDMA?
Could microdosing be dangerous?
Is there such a thing as DMT tolerance?
David E. Nichols, is currently an Adjunct Professor in the Eshelman School of Pharmacy at the University of North Carolina, Chapel Hill, NC. He is a Distinguished Professor Emeritus at the Purdue University College of Pharmacy, and was the Robert C. and Charlotte P. Anderson Chair in Pharmacology, where he carried out teaching and research for 38 years prior to his retirement in 2012. A major focus of his research was on substances known as hallucinogens, known more popularly as psychedelics. Widely published in the scientific literature and internationally recognized for his research on centrally active drugs, he has studied all of the major classes of psychedelic agents, including LSD and other lysergic acid derivatives, psilocybin and the tryptamines, and phenethylamines related to mescaline. Among scientists, he is recognized as one of the foremost international experts on the medicinal chemistry of psychedelics.